Lakefront Biotherapeutics
LKFT
30.00
+0.68
+2.32%
Lakefront Biotherapeutics
US · LKFT
#2803 by market cap
Listed 1970
30.00
+0.68
+2.32%
Live - 5344 symbols - heartbeat 379s ago
· 2026-10-08 08:22
Pre-market
29.42
-1.93%
After-hours
30.00
0.00%
Overnight
29.31
-2.30%
- Market cap
- 1.96B
- P/E (TTM)i
- 2.96
- P/Bi
- 0.54
- EPSi
- 5.45
- Div yieldi
- 0.00%
- 52W posi
- 41%
Reader sentiment
Are you bullish or bearish on LKFT?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 8.84, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +303.50% YoY
Margins
- Gross margin
- 97.33%
- Operating margin
- 45.08%
- Net margin
- 28.85%
Key ratios & quality
- Altman Z-Scorei
- 8.84
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 278.67M | 834.90M | 478.05M | 234.38M | 241.25M | 239.72M | 275.65M | 1.11B |
| Gross profit | -- | 834.90M | 478.05M | -- | 241.25M | 239.72M | 240.79M | 1.08B |
| Selling & admin expenses | 32.91M | 87.35M | 158.02M | 89.24M | 103.31M | 94.25M | 96.88M | 111.96M |
| Research & development | 316.22M | 420.09M | 523.67M | 320.50M | 269.80M | 241.29M | 335.46M | 459.42M |
| Operating profit | -47.08M | 368.75M | -178.63M | -171.57M | -131.06M | -88.26M | -188.34M | 501.39M |
| Pretax profit | -31.42M | 148.53M | -309.78M | -119.40M | -70.85M | 5.63M | -3.09M | 300.87M |
| Tax | 822.00K | -165.00K | 1.23M | 1.39M | 572.00K | 9.61M | -1.80M | -18.62M |
| Net profit | -29.26M | 149.85M | -305.44M | -103.23M | -217.99M | 211.70M | 74.08M | 320.88M |
| Basic EPS | -1 | 3 | -5 | -2 | -3 | 3 | 1 | 5 |
| Diluted EPS | -0.56 | 2.49 | -4.69 | -1.58 | -3.32 | 3.21 | 1.12 | 4.87 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 74.98M | 65.29M | 71.16M | 900.82M | 6.48M | 12.11M |
| Gross profit | 61.25M | 60.58M | 60.32M | 900.37M | 1.68M | 2.97M |
| Selling & admin expenses | 43.80M | 18.80M | 46.42M | 2.94M | 35.51M | 7.51M |
| Research & development | 182.75M | 95.28M | 73.88M | 107.51M | 30.96M | 25.52M |
| Operating profit | -158.71M | -57.03M | -41.67M | 758.80M | -63.70M | -43.51M |
| Pretax profit | -156.37M | -104.42M | -221.49M | 783.16M | 13.96M | 2.01M |
| Tax | -1.81M | 26.00K | -17.50M | 666.00K | 70.00K | 70.00K |
| Net profit | -153.40M | -105.75M | -202.11M | 782.15M | 14.49M | 2.11M |
| Basic EPS | -2 | -2 | -3 | 12 | 0 | 0 |
| Diluted EPS | -2.33 | -1.60 | -3.07 | 11.87 | 0.22 | 0.03 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 1.33B | 5.87B | 5.37B | 4.86B | 4.24B | 3.86B | 3.34B | 3.08B |
| Cash & ST investments | 1.29B | 5.78B | 5.16B | 4.70B | 4.09B | 3.68B | 3.12B | 3.00B |
| Inventory | 276.00K | 255.00K | 355.00K | 20.57M | 52.93M | 73.98M | 51.19M | 22.49M |
| Total assets | 1.44B | 6.07B | 5.72B | 5.19B | 4.73B | 4.36B | 4.14B | 3.41B |
| Total current liabilities | 219.91M | 571.79M | 635.27M | 566.47M | 522.54M | 428.22M | 335.08M | 152.86M |
| Short-term debt | -- | 5.83M | 6.40M | 7.20M | 7.21M | 4.65M | 3.48M | 1.73M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 225,247,000.00 | 3,192,951,000.00 | 3,047,376,000.00 | 2,549,798,000.00 | 2,208,325,000.00 | 1,561,830,000.00 | 1,238,780,000.00 | 170,650,000.00 |
| Total equity | 1.21B | 2.88B | 2.67B | 2.64B | 2.53B | 2.80B | 2.90B | 3.24B |
| Retained earnings | -297.78M | -109.22M | -334.70M | -367.21M | -496.69M | -228.27M | -134.31M | 210.58M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 3.47B | 3.26B | 3.16B | 3.08B | 3.06B | 2.31B |
| Cash & ST investments | 3.30B | 3.09B | 3.05B | 3.00B | 2.98B | 2.24B |
| Inventory | 38.52M | 33.79M | 22.95M | 22.49M | 17.69M | 8.54M |
| Total assets | 4.02B | 3.82B | 3.51B | 3.41B | 3.37B | 3.35B |
| Total current liabilities | 437.04M | 402.95M | 366.56M | 152.86M | 100.42M | 70.32M |
| Short-term debt | 3.07M | 2.39M | 1.74M | 1.73M | 1.58M | 1.59M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 1,274,052,000.00 | 1,174,405,000.00 | 1,064,951,000.00 | 170,650,000.00 | 119,060,000.00 | 87,558,000.00 |
| Total equity | 2.75B | 2.64B | 2.45B | 3.24B | 3.25B | 3.26B |
| Retained earnings | -280.81M | -380.80M | -577.74M | 210.58M | 228.33M | 233.96M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -142.47M | 3.21B | -427.34M | -503.83M | -500.54M | -405.97M | -320.03M | -257.46M |
| Depreciation & amortization | 5.08M | 12.45M | 18.68M | 34.64M | 65.57M | 43.64M | 45.50M | 55.88M |
| Free cash flow | -156.18M | 3.16B | -518.65M | -561.71M | -537.49M | -425.24M | -402.14M | -271.32M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 296.19M | 960.09M | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 1.29B | 1.86B | 2.14B | -- | 508.12M | 166.81M | 64.24M | 87.87M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -38.61M | -108.78M | -62.61M | -47.46M | -82.75M | -34.09M |
| Depreciation & amortization | -- | -- | -- | -- | -- | -- |
| Free cash flow | -43.86M | -112.94M | -65.46M | -49.07M | -82.87M | -34.12M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 108.07M | 71.67M | 64.46M | 87.87M | 66.81M | 135.95M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -2.63 | 7.33 | -11.01 | -3.89 | -8.43 | 7.96 | 2.60 | 10.46 |
| ROA %i | -2.15 | 3.99 | -5.18 | -1.89 | -4.39 | 4.66 | 1.74 | 8.51 |
| ROIC %i | -2.92 | 6.64 | -10.92 | -3.61 | -8.67 | 5.75 | 0.28 | 9.37 |
| 5-year avg ROE %i | -5.95 | -8.04 | -1.95 | -4.65 | -3.73 | -1.61 | -2.56 | 1.74 |
| EBIT margin %i | -9.84 | 17.91 | -62.84 | -22.96 | -41.20 | 3.08 | -0.79 | 27.25 |
| FCF / sales %i | -- | 374.32 | -- | -- | -- | -- | -- | -- |
| Current ratioi | 6.04 | 10.26 | 8.45 | 8.58 | 8.11 | 9.02 | 9.97 | 20.15 |
| Quick ratioi | 6.02 | 10.25 | 8.40 | 8.53 | 7.98 | 8.76 | 9.57 | 19.96 |
| Debt / assetsi | 0.00 | 0.42 | 0.51 | 0.52 | 0.46 | 0.22 | 0.28 | 0.20 |
| LT debt / equityi | -- | 0.68 | 0.86 | 0.74 | 0.58 | 0.18 | 0.28 | 0.16 |
| Interest coveragei | -36.45 | 116.25 | -31.99 | -9.55 | -29.88 | 4.18 | -2.39 | 136.71 |
| Revenue CAGR (3Y) %i | 91.69 | 86.11 | 55.52 | -5.61 | -33.89 | -20.55 | 5.55 | 66.44 |
| Net income CAGR (3Y) %i | -- | 40.51 | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | 138.00 | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -6.01 | -10.24 | -16.42 | 10.46 | 16.29 | 20.20 |
| ROA %i | -4.04 | -7.01 | -11.35 | 8.51 | 13.22 | 16.64 |
| ROIC %i | -8.65 | -12.37 | -16.36 | 9.37 | 15.30 | 19.16 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -44.33 | -105.09 | -46.69 | 27.25 | 38.14 | 58.45 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 7.95 | 8.08 | 8.63 | 20.15 | 30.48 | 32.84 |
| Quick ratioi | 7.74 | 7.89 | 8.53 | 19.96 | 30.23 | 32.65 |
| Debt / assetsi | 0.27 | 0.22 | 0.21 | 0.20 | 0.19 | 0.19 |
| LT debt / equityi | 0.28 | 0.23 | 0.24 | 0.16 | 0.15 | 0.15 |
| Interest coveragei | -- | -227.52 | -- | 136.71 | -- | 419.88 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Single segment100.00%
Region
United States of America97.20%
Europe2.80%
Quote time 2026-10-08 08:22:25 · For reference only, not investment advice and not tailored to your situation.